+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating the safety, effectiveness, and treatment experience of participants prescribed BRIUMVI4 ublituximab-xiiy for relapsing multiple sclerosis RMS in a real-world setting. The study aims to gather insights over time on how this treatment works outside of controlled clinical trials. Participants will receive BRIUMVI4 ublituximab-xiiy through intravenous infusion as part of their routine care for RMS. This observational study follows these participants longitudinally to monitor their health and treatment experience without assigning any new interventions. During the study, participants will be monitored for relapses, adverse events, and infusion-related reactions up to 96 weeks. Researchers will collect data from medical records and routine visits to assess annualized relapse rates and safety outcomes, supporting a comprehensive understanding of treatment effects in everyday clinical practice. The study duration extends until 2032, allowing for long-term follow-up.

Age: 18Years +All Genders
113 locations
H

Actively Recruiting

Healthy Volunteer

This observational study evaluates the measurement of blood p-tau217 levels, a biomarker related to Alzheimers disease, using a home-based Tasso lancet device compared to the standard venipuncture blood collection method. The study includes participants with Alzheimers disease confirmed by amyloid PET or cerebrospinal fluid tests, healthy individuals without cognitive impairment, and people with cognitive impairment not caused by Alzheimers disease who are amyloid-negative. Researchers aim to compare p-tau217 concentrations in these different groups to assess agreement between the two blood collection methods. Participants are divided into three groups those with Alzheimers disease confirmed by amyloid PET or CSF, healthy controls without cognitive impairment, and individuals with non-Alzheimers cognitive impairment confirmed to be amyloid-negative. Blood samples will be collected at home using the Tasso device and also by standard venipuncture for comparison. The study focuses on baseline measurements of p-tau217 concentration agreement between these two collection methods. During the study, participants will provide blood samples through both methods, with assistance and caregiver consent available if needed. The primary outcome measured is the agreement between p-tau217 levels in blood collected by the Tasso device and by venipuncture at baseline. The study plans to enroll adults aged 40 to 90 years and includes safety monitoring related to systemic health conditions and recent medical history. Overall participation involves blood collection and monitoring without therapeutic intervention.

Age: 40Years - 90YearsAll Genders
5 locations
C

Actively Recruiting

Researchers are studying relapsing multiple sclerosis RMS in this Phase 3b trial to compare the effects of switching from the drug ocrelizumab to remibrutinib versus continuing ocrelizumab treatment. The goal is to assess whether remibrutinib is similarly effective, safe, and tolerable for people living with RMS. This study is randomized, open-label, and conducted across multiple centers globally, including the USA. Participants will be randomly assigned to either switch to oral remibrutinib daily or continue their standard ocrelizumab treatment, which is given by infusion or injection. The study includes an initial Core Part lasting up to 24 months, during which efficacy and safety are closely monitored. After completing this phase, eligible participants may join an Extension Part of up to 24 months where all receive remibrutinib in an open-label format. During the study, participants will undergo regular assessments including MRI scans to measure new or enlarging brain lesions, neurological evaluations, and monitoring for adverse events. Researchers will track disease activity, safety, and tolerability throughout both study parts. The total participation time may be up to 48 months, providing long-term data on remibrutinib following ocrelizumab treatment.

Age: 40Years - 70YearsAll GendersPhase 3
131 locations
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations